874285-19-5

Basic information

• Product Name: 2-Chloro-3-fluorobenzyl bromide
• Synonyms: 2-Chloro-3-fluorobenzyl bromide;1-(BroMoMethyl)-2-chloro-3-fluorobenzene
• CAS NO: 874285-19-5
• Molecular Formula: C₇H₅BrClF
• Molecular Weight: 223.47
• Product Categories: Fluorine series
• Mol File: 874285-19-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 227.1 °C at 760 mmHg
• Flash Point: 91.1 °C
• Appearance: /
• Density: 1.654 g/cm³
• Vapor Pressure: 0.119mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-Chloro-3-fluorobenzyl bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-3-fluorobenzyl bromide(874285-19-5)
• EPA Substance Registry System: 2-Chloro-3-fluorobenzyl bromide(874285-19-5)

Safety Data

• Hazardous Substances Data: 874285-19-5(Hazardous Substances Data)

Usage

Uses

2-Chloro-3-fluorobenzyl Bromide is a reagent used as an integrase strand-transfer inhibitor.

InChI:InChI=1/C7H5BrClF/c8-4-5-2-1-3-6(10)7(5)9/h1-3H,4H2

Upstream product

• 96516-32-4 (2-chloro-3-fluorophenyl)methanol 
• 102940-86-3 3-chloro-3-fluorobenzoic acid 

Downstream Products

• 1240660-10-9 3-acetyl-1-(2-chloro-3-fluorobenzyl)-4-methoxy-1H-indole 

Relevant articles and documents

Discovery of Highly Potent Liver X Receptor β Agonists

Introducing a uniquely substituted phenyl sulfone into a series of biphenyl imidazole liver X receptor (LXR) agonists afforded a dramatic potency improvement for induction of ATP binding cassette transporters, ABCA1 and ABCG1, in human whole blood. The ag

Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors

Human immunodeficiency virus type 1 (HIV-1) integrase is a crucial target for antiretroviral drugs, and several keto - enol acid class (often referred to as diketo acid class) inhibitors have clinically exhibited-marked antiretroviral activity. Here, we show the synthesis and the detailed structure - activity relationship of the quinolone carboxylic acids as a novel monoketo acid class of integrase inhibitors. 6-(3-Chloro-2-fluorobenzyl)-1-((2S)-1-hydroxy-3,3- dimethylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 51, which showed an IC50 of 5.8 nMin the strand transfer assay and an ED50 of 0.6 nMin the antiviral assay, and 6-(3-chloro-2-fluorobenzyl) -1-((2S)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3- carboxylic acid 49, which had an IC50 of 7.2 nMand an ED50 of 0.9 nM, were the most potent compounds in this class. The monoketo acid 49 was much more potent at inhibiting integrasecatalyzed strand transfer processes than 3′-processing reactions, as is the case with the keto - enol acids. Elvitegravir 49 was chosen as a candidate for further studies and is currently in phase 3 clinical trials.